Loop Genomics has secured $8.0 million in investment capital from investors, marking a significant funding round for the company. The funding will support the continued development and commercialization of its unique genomics technology. Loop Genomics specializes in a hardware-free synthetic long read sequencing approach, designed to transform any existing short read sequencer into a single molecule long read sequencer.
The company's proprietary technology involves specialized sample preparation and software. This system tags DNA/RNA molecules with DNA barcodes, which are then copied and distributed intra-molecularly throughout long molecules. These barcoded libraries are subsequently converted into standard short read libraries and sequenced on any conventional short read sequencer. Following sequencing, Loop Genomics' software groups reads with identical barcodes, assembling them back into the longer molecules that were originally tagged. This process enables the assembly of genomes, transcriptomes, or targeted amplicons from long reads, providing highly accurate, single molecule long read data without requiring new hardware investments.
This funding round underscores the growing interest in technologies that enhance genomic sequencing capabilities. The $8.0 million in capital is earmarked to accelerate Loop Genomics' growth initiatives, including expanding its research and development efforts and scaling its operational capacity. The investment is expected to enable the company to further refine its technology and broaden its market reach, making advanced long-read sequencing more accessible to a wider range of laboratories and applications. Loop Genomics aims to continue its trajectory of innovation, solidifying its position in the genomics sector.
